CleneCLNN
CLNN
About: Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Employees: 76
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
0.88% less ownership
Funds ownership: 6.16% [Q4 2024] → 5.28% (-0.88%) [Q1 2025]
11% less funds holding
Funds holding: 27 [Q4 2024] → 24 (-3) [Q1 2025]
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
46% less capital invested
Capital invested by funds: $2.6M [Q4 2024] → $1.4M (-$1.2M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
555%
upside
Avg. target
$28
698%
upside
High target
$33
840%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 555%upside $23 | Buy Maintained | 18 Jul 2025 |
Benchmark Bruce Jackson | 840%upside $33 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene's NIH-sponsored Expanded Access Program NfL EAP biomarker analyses to be conducted early in the 4 th Quarter of 2025 Clene confirms two additional FDA meetings scheduled for 3 rd Quarter of 2025, to discuss ALS survival data and MS clinical development program Submission of new drug application for ALS under the accelerated approval pathway on track for potential submission in the 4 th Quarter of 2025 SALT LAKE CITY, June 30, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today provided a regulatory update following a Type C meeting with the U.S. Food and Drug Administration (FDA), and announced two additional meetings scheduled with the FDA in the 3rd quarter of 2025. In the recently concluded Type C meeting, Clene discussed its proposed statistical analysis plan (SAP) for comparing neurofilament light (NfL) biomarker data from its ongoing NIH-sponsored Expanded Access Protocol (EAP), supporting nearly 200 people living with ALS treated with compassionate use of CNM-Au8®, to matched ALS controls.
Neutral
Accesswire
1 month ago
Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025
SALT LAKE CITY, UT / ACCESS Newswire / June 9, 2025 / Clene Inc. announced that Rob Etherington, Chief Executive Officer and President, will be presenting at the Investor Summit Virtual taking place on June 10. About Clene Inc. Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.
Negative
Zacks Investment Research
2 months ago
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $1.80 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker data Clene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL data Clene reported new data supporting the remyelination and neuronal repair associated with CNM-Au8 ® treatment in a late-breaking science session at the American Academy of Neurology (AAN) 2025 Annual Meeting Clene released new data from a cross-regimen analysis of HEALEY ALS Platform Trial, showing that CNM-Au8 significantly extends survival in patients with ALS Clene planning to submit a New Drug Application (NDA) in the fourth quarter of 2025 for potential Accelerated Approval of CNM-Au8 in ALS Cash and cash equivalents of $9.8 million as of March 31, 2025, providing cash runway into the third quarter of 2025 SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its first quarter 2025 financial results and provided recent updates on its CNM-Au8 programs. “Prolonging survival for people living with ALS is the critical mission for Clene.
Neutral
GlobeNewsWire
3 months ago
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
Neutral
GlobeNewsWire
3 months ago
Clene to Present at the Jones Healthcare and Technology Innovation Conference
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Jones Healthcare and Technology Innovation Conference and host 1x1 investor meetings.
Negative
Zacks Investment Research
4 months ago
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.20 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2024 financial results and provided recent operating highlights for the clinical programs in ALS and MS.
Neutral
GlobeNewsWire
4 months ago
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival Advantage
Neutral
GlobeNewsWire
4 months ago
Clene to Present at the 37TH Annual Roth Conference
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings.
Charts implemented using Lightweight Charts™